The activation of the Rb‐Raf‐1/Phospho‐ERK/Phospho‐P90SRK signaling pathway provides a gate through which E2F1 can enter and further contribute to the tumor development and proliferation process in NSCLC [106, 107], while this pathway also activates the antiapoptotic protein mitochondrial Bcl‐2 in lung cancer [68, 108], thereby validating the effective engagement of the α7 subtype for survival in lung cancer. This evidence concerns the gene MAPK1 and lung carcinoma.